Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.52 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.50 |
| ▸ | MME | P08473 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PAM | P19021 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5913037 | 1.00 | CYP3A4 (0.66) | CYP3A4CYP2C9RECQLAKR1C3AKR1C1 | |
| SCHEMBL261986 | 1.00 | CYP3A4 (0.66) | CYP3A4CYP2C9RECQLAKR1C3AKR1C1 | |
| SCHEMBL21051784 | 0.89 | CYP2C9 (0.58) | CYP3A4CYP2C9RECQLAKR1C3AKR1C1 | |
| SCHEMBL21051783 | 0.89 | CYP2C9 (0.58) | CYP3A4CYP2C9RECQLAKR1C3AKR1C1 | |
| SCHEMBL194183 | 0.83 | CYP3A4 (0.52) | CYP3A4CYP2C9RECQLAKR1C3AKR1C1 | |
| SCHEMBL22511016 | 0.83 | RECQL (0.70) | CYP3A4CYP2C9RECQLAKR1C3AKR1C1 | |
| SCHEMBL5698377 | 0.83 | CYP3A4 (0.61) | CYP3A4CYP2C9RECQLAKR1C3AKR1C1 | |
| SCHEMBL3183037 | 0.82 | CYP3A4 (0.50) | CYP3A4CYP2C9RECQLAKR1C3AKR1C1 | |
| SCHEMBL1274022 | 0.81 | CYP3A4 (0.63) | CYP3A4CYP2C9RECQLAKR1C3AKR1C1 | |
| SCHEMBL9068476 | 0.81 | CYP3A4 (0.63) | CYP3A4CYP2C9RECQLAKR1C3AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0937710-B1 | Method for producing an optically active phenylpropionic acid derivative | AJINOMOTO KK (JP) | 2003-04-16 | — | — | EP | disclosed |
| EP-0906901-B1 | Process for producing propionic acid derivatives | AJINOMOTO KK (JP) | 2002-03-27 | — | — | EP | disclosed |
| US-6339170-B2 | CONDENSATION OF 2-HYDROXYMETHYL-3-PHENYLPROPIONIC ACID AND GLYCINE BENZYL ESTER, CONVERSION OF HYDROXYL GROUP TO ELIMINATION GROUP, SUBSTITUTION BY ACETYLTHIO GROUP; ENKEPHALIN AND ACETYLCHOLINESTERASE INHIBITORS | AJINOMOTO CO., INC. (JP) | 2002-01-15 | — | — | US | disclosed |
| US-20010014754-A1 | Method for producing optically active phenylpropionic acid derivative | AJINOMOTO CO., INC. (JP) | 2001-08-16 | — | — | US | disclosed |
| US-6242635-B1 | THROUGH SHORT SYNTHESIS ROUTE INDUSTRIALLY SAFE AND EASILY; USED IN PRODUCING OPTICALLY ACTIVE SUBSTANCE CONVERTIBLE INTO A LENIN INHIBITOR INTERMEDIATE, ENKEPHALINASE INHIBITOR, OR PROTEASE INHIBITOR | AJINOMOTO CO., INC. (JP) | 2001-06-05 | — | — | US | disclosed |
| US-6239305-B1 | REACTING A N-ACYLAMINO ACID ESTER WITH A THIOACETIC ACID | AJINOMOTO CO., INC. (JP) | 2001-05-29 | — | — | US | disclosed |
| US-6031121-A | Method for producing optically active phenylpropionic acid derivative | AJINOMOTO CO., INC. (JP) | 2000-02-29 | — | — | US | disclosed |
| EP-0937710-A1 | Method for producing an optically active phenylpropionic acid derivative | Ajinomoto Co., Inc. (JP) | 1999-08-25 | — | — | EP | disclosed |
| EP-0906901-A2 | Process for producing propionic acid derivatives | Ajinomoto Co., Inc. (JP) | 1999-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010014754-A1 | Method for producing optically active phenylpropionic acid derivative | ACE, DNPEP, AGT | CYP3A4 902/4885CYP2C9 1169/4885RECQL 4840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.